BCA
CGTX icon

Bray Capital Advisors’s Cognition Therapeutics CGTX Stock Holding History

Bray Capital Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1.58K Hold
2,250
– – ﹤0.01% 250
2024
Q3 		$1.05K Hold
2,250
– – ﹤0.01% 253
2024
Q2 		$3.73K Hold
2,250
– – ﹤0.01% 241
2024
Q1 		$4.09K Hold
2,250
– – ﹤0.01% 247
2023
Q4 		$4.16K Hold
2,250
– – ﹤0.01% 246
2023
Q3 		$3.24K Hold
2,250
– – ﹤0.01% 248
2023
Q2 		$4.12K Hold
2,250
– – ﹤0.01% 248
2023
Q1 		$4.46K Hold
2,250
– – ﹤0.01% 251
2022
Q4 		$4.72K Hold
2,250
– – ﹤0.01% 250
2022
Q3 		$4K Hold
2,250
– – ﹤0.01% 268
2022
Q2 		$5K Buy
+2,250
New +$5.81K ﹤0.01% 255
2022
Q1 		– Sell
-250
Closed -$2K – 277
2021
Q4 		$2K Buy
+250
New +$2.44K ﹤0.01% 269

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bray Capital Advisors's CGTX Position: Q4 2024 in Review

Bray Capital Advisors held its Cognition Therapeutics (CGTX) position steady in Q4 2024 at 2,250 shares worth $1.58K. The position accounts for ﹤0.01% of the portfolio, ranked #250.

Bray Capital Advisors first reported a position in CGTX in Q4 2021 and has held it in 12 quarters since. The position peaked at $5K in Q2 2022. 45 funds tracked by Wall St. Rank hold CGTX as of Q4 2024.

  • Bray Capital Advisors held 2,250 shares of Cognition Therapeutics worth $1.58K as of Q4 2024.
  • Bray Capital Advisors left its Cognition Therapeutics share count unchanged in Q4 2024.
  • Cognition Therapeutics made up ﹤0.01% of Bray Capital Advisors's portfolio in Q4 2024, its #250 holding.
  • Bray Capital Advisors first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Bray Capital Advisors's Cognition Therapeutics position peaked at $5K in Q2 2022.
  • 45 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q4 2024.

Based on Bray Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.